{
  "docId": "019de070-a5cb-72a4-ac7d-0f26e10cd805",
  "docSlug": "05d98084f9bd31c78a17b84718191aae",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 39,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 10,
  "notes": "Includes footnotes explaining specific financial metrics and product categories.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-a5cb-72a4-ac7d-0f26e10cd805/6",
  "deckHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805",
  "deckJsonHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805.json",
  "deckAnchorHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for full-year (FY) 2020, unless stated otherwise. Guidance at CER and excludes COVID-19 Vaccine AstraZeneca and Alexion.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ba2c79c-9a38-41fd-9b5d-24c43a6ec9eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.95,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "list",
      "text": "Key highlights: Total revenue up by 10%; Revenue growth: new medicines +33%, Oncology +24%, New CVRM +9%; Core operating profit up by 17%; Core EPS $4.02 (+18%); Cash improving at $4.8bn; Pipeline progress; ESG: COVID-19 vaccine progress; 2021 guidance.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "726bc937-8dea-43b8-90ae-c5b810b46087",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "FY 2020: strong and resilient double-digit performance",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d97afef-4db8-4b23-9f7c-4dbc2181269c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 6,
      "beatId": "eed16d83-03b8-4ec5-a24a-dadc1a82219d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Attention",
      "beatSlug": "monroes-sequence-attention",
      "evidence": "The document grabs attention with strong KPIs and key takeaways",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}